TradingKey - As of May 7, the World Health Organization (WHO) has confirmed eight cases of hantavirus infection associated with the cruise ship, including three deaths. The Andes strain of the virus is the only hantavirus subtype known to be capable of limited person-to-person transmission.

TradingKeySun, May 10

Is Novo Nordisk Positioned for Recovery in 2026 Amid Rising Competition and AI Innovations?

TradingKey - Since 1923, Novo Nordisk (NVO) has thrived as a pharmaceutical company based in Denmark, primarily focusing on two business areas: Obesity and diabetes, and Rare Diseases.

TradingKeyMon, May 4

GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

TradingKey - On April 16, 2026, OpenAI released GPT-Rosalind, a large language model specifically designed for life sciences research. Initial users include pharmaceutical giant Amgen (AMGN), vaccine manufacturer Moderna (MRNA), and the Allen Institute. Following the announcement, the CRO sector saw a broad decline, with IQVIA Holdings (IQV) falling 3.5% and Charles River Laboratories (CRL) dropping 2.6%. Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) both tumbled over 5% at one point.

TradingKeyFri, Apr 17

Cross-Sector Collaboration Between Pharma and AI. Novo Nordisk Joins Forces With OpenAI, Can It Regain Market Dominance in the Competition With Eli Lilly?

TradingKey - Danish pharmaceutical manufacturer Novo Nordisk (NOVO) stated on Tuesday that it will partner with OpenAI to deploy artificial intelligence across all aspects of its business, from drug discovery to manufacturing and commercial operations.

TradingKeyWed, Apr 15

Revolution Medicines Doubles Pancreatic Cancer Survival in Phase 3 Trial — Is RVMD Stock a Buy at $136?

TradingKey - RVMD surged 41% after Phase 3 pancreatic cancer data doubled survival vs chemo. Analysts target $147–$165. Key support $125–$120. May 6 earnings next.

TradingKeyTue, Apr 14

Gilead's Stock Price is Expected to Rise to $160，Gilead’s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America

TradingKey - Gilead Sciences has confirmed its intention to acquire Tubulis (Germany) for a maximum value of up to $5 billion dollars. This acquisition is expected to add considerable strength to Gilead's pipeline for oncology products and provide them with greater access to the developing market fo

TradingKeyWed, Apr 8

KeyAI

